Current guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs), particularly spironolactone and eplerenone, to reduce adverse cardiovascular events in heart failure (5, 6, 10).Emerging evidence has shown that a novel nonsteroidal selective MRA, finerenone, exhibits more pronounced anti-inflammatory and antifibrotic effects (11). Here, NR3C2 is linked to heart failure.